HTLV-1-Associated Myelopathy (HAM) Incidence in Asymptomatic Carriers and Intermediate Syndrome (IS) Patients
Pathogens · 2024
DOI: 10.3390/pathogens13050403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Rosa Maria do Nascimento Marcusso und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Infectologia Emílio Ribas, São Paulo 01246-000, Brazil. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MRC, Fapesp, Fundação Faculdade de Medicina.
Abstract (Originalsprache)
Several studies suggest that HTLV-1 infection may be associated with a wider spectrum of neurological and clinical manifestations that do not meet diagnostic criteria for HAM. These conditions may later progress to HAM or constitute an intermediate clinical form: intermediate syndrome (IS), a mid-point between asymptomatic HTLV-1 carriers and those with full myelopathy. Thus, we determined the incidence of HAM cases in the HTLV-1-asymptomatic and IS patients, and the clinical/laboratory associated markers. A total of 204 HTLV-1-positive patients were included in this study, divided into two groups: Group 1, including 145 asymptomatic HTLV-1 subjects (ASY), and Group 2, including 59 patients with inflammatory clinical symptoms in more than three systems and a high proviral load (PVL). During a 60-month follow-up time, with the age ranging from 47 to 79 years, ten patients of the fifty-nine initially diagnosed as IS developed HAM (iHAM), and two patients of the initial 145 ASY developed HAM directly. Women were more prevalent in all groups. For the iHAM patients, the age ranged from 20 to 72 years, with a mean of 53 (±15 SD). Older age was associated with the development of HAM, higher PVL and IS; however, there was no any specific symptom or clinical sign, that was associated with risk for iHAM. In conclusion, IS cases could be an early phase of development of HAM. These findings show the presence of higher incidence probabilities in our cohort than previously reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Infectologia Emílio Ribas, São Paulo 01246-000, Brazil.
- Departamento de Medicina Legal, Bioética, Medicina do Trabalho e Medicina Física e Reabilitação, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil.
- Departamento de Dermatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil.
- Section of Virology, Department of Infectious Disease, Imperial College London, London SW7 2BX, UK.
ORCID-Profile: Rosa Maria do Nascimento Marcusso, Tatiane Assone, Michel E Haziot, Victor A Folgosi, Carolina Rosadas, Jorge Casseb
Förderung
- MRC
- Fapesp
- Fundação Faculdade de Medicina
Zitieren
APA
Marcusso, R. M. D. N., Assone, T., Haziot, M. E., Smid, J., Folgosi, V. A., Rosadas, C., Casseb, J., de Oliveira, A. C. P., & The Htlv-Clinical Definition Working Group (2024). HTLV-1-Associated Myelopathy (HAM) Incidence in Asymptomatic Carriers and Intermediate Syndrome (IS) Patients. Pathogens. https://doi.org/10.3390/pathogens13050403
Vancouver
Marcusso RMDN, Assone T, Haziot ME, Smid J, Folgosi VA, Rosadas C, et al. HTLV-1-Associated Myelopathy (HAM) Incidence in Asymptomatic Carriers and Intermediate Syndrome (IS) Patients. Pathogens. 2024. doi:10.3390/pathogens13050403
BibTeX
@article{Marcusso2024,
author = {Marcusso, Rosa Maria do Nascimento and Assone, Tatiane and Haziot, Michel E and Smid, Jerusa and Folgosi, Victor A and Rosadas, Carolina and Casseb, Jorge and de Oliveira, Augusto C Penalva and The Htlv-Clinical Definition Working Group},
title = {HTLV-1-Associated Myelopathy (HAM) Incidence in Asymptomatic Carriers and Intermediate Syndrome (IS) Patients},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13050403}
}
EUVIMED